Review links some targeted lung cancer drugs with higher cardiac-event odds
A network meta-analysis found cardiovascular safety differences among EGFR inhibitors used for a specific genetic form of lung cancer.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review found higher odds of cardiac adverse events with first- and third-generation EGFR inhibitors than with placebo. Direct pooled comparisons also linked third-generation drugs with more cardiovascular adverse events than first-generation drugs. These are treatment-specific safety findings in people with EGFR-mutated lung cancer, rather than an assessment of each drug's overall benefits and harms.
The abstract summarizes several drugs and cardiovascular outcomes. It does not provide the individual patient characteristics or benefit data needed to translate these pooled safety comparisons into a treatment choice.
What researchers found
Cardiac adverse events with third-generation EGFR inhibitors
Compared with placebo; the review's mean follow-up was 2.18 years. Evidence certainty for this comparison was rated high.
Different cardiovascular outcomes
The review distinguished cardiac events, vascular events and abnormal heart rhythms. Some drug combinations were associated with vascular or broader cardiovascular problems, while third-generation inhibitors also showed an arrhythmia signal. These endpoints should not be treated as interchangeable.
Reading the odds ratio
The reported estimate compares the odds of cardiac events between treatments. It is not an individual's probability of an event or a percentage increase in absolute risk. The abstract does not provide a matching placebo event rate.
The original publication
Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.
Ma Z, Cao F, Liao M et al.
BMJ · 2025
- PubMed ID
- 40897431
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.